Allergy Therapeutics Progresses Grass And Peanut Allergy Vaccines, Plans For US Entry
Clinical studies of grass allergy and peanut allergy vaccines are expected to start this year, as the UK specialty company plots its entry into the US.
You may also be interested in...
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.
Increasing patient and doctor awareness of sublingual anti-allergy tablets in the US, while at the same time cutting and rationalizing its product portfolio, are components of a new three-year business strategy aimed at making Denmark's ALK-Abello a less-niche player in the global allergy market.